Source: Nature
Private capital from tech entrepreneurs is now a meaningful force in biomedical research, displacing traditional gatekeepers like government agencies and academic institutions. The shift accelerates certain research areas (AI-driven drug discovery, longevity science) while potentially starving others (rare diseases, basic biology without commercial endpoints). Funding decisions concentrated in the hands of individuals with tech-sector incentive structures create both a speed advantage and a structural risk: these funders tend to favor moonshot narratives and measurable outcomes over the unglamorous, long-term foundational work that has historically fueled scientific breakthroughs.